Drugs / ASP-1929 Photoimmunotherapy
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06699212 | Dec 2024 → Sep 2028 expected | head and neck squamous cell carcinoma | Rakuten Medical, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASP-1929 Photoimmunotherapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06699212 ↗ |
| Route | Intravenous | “ASP-1929 IV infusion followed by illumination with light dose of 50 J/cm\^2 for superficial lesions and 100 J/cm for interstitial lesions within 24 +/- 4 hours after the end of...” NCT06699212 ↗ |